On November 22, 2024, Vietnam Report, a reputable rating company, officially announced the “Top 10 Vietnam Pharmacy Reputation Award 2024”. Ha Tay Pharmaceutical Joint Stock (Hataphar) Company is honored to be included in this ranking, marking the 8th consecutive year that Hataphar has been named among the top 10 most prestigious pharmaceutical manufacturers in Vietnam.
The “Top 10 Most Prestigious Pharmaceutical Manufacturing Companies in 2024” is the result of independent and objective research conducted annually by Vietnam Report since 2016, based on scientific and objective principles with three main criteria:
- Financial capacity reflected in the latest annual financial report
- Media reputation assessed using the Media Coding method – a press data coding tool.
- Customer surveys, relevant stakeholders, and industry experts conducted in October-November 2024.
The 8th time being included in the “Top 10 Most Prestigious Pharmaceutical Manufacturing Companies in 2024” is both a source of pride for all employees and leaders of Hataphar for our continuous efforts and increasingly better results, as well as an affirmation of the quality and reputation of the Hataphar brand, which has been associated with Vietnamese healthcare for nearly 60 years and is now on the path to international integration.
According to Vietnam Report’s survey, after a strong 2023, the growth momentum of the pharmaceutical, medical equipment, and healthcare industry has slowed down in the first 10 months of 2024 due to challenges related to fluctuations in input material prices, declining purchasing power due to the trend of tightening consumer spending, and slow circulation of some anti-epidemic products. The increasing competition has made the overall market less favorable in the early months of the year.
However, in the long term, the pharmaceutical, medical equipment, and healthcare market is still considered to have high growth potential despite potential risks in the market. Strong drivers for Vietnam’s healthcare market, in addition to government support policies, amendments to the Pharmaceutical Law, population structure, and increasing healthcare needs, also include globalization and international integration, creating opportunities for businesses to access the global value chain more deeply.
With the CNC Hataphar factory project in collaboration with strategic partner ASKA Pharmaceutical (a top 20 pharmaceutical company in Japan with over 100 years of pharmaceutical manufacturing experience) about to come into operation, Hataphar is also getting closer to its goal of innovation and international integration. This not only affirms the Hataphar brand and position domestically but also reaches further into the global market.
